How Increased Use of Gene Therapy Treatment for Sickle Cell Disease Could Affect the Federal Budget

Congressional Budget Office

No 60775, Reports from Congressional Budget Office

Abstract: Gene therapies replace or modify disease-causing genes in human cells. Those therapies, which are still relatively new, are used to prevent, cure, or treat the symptoms of a particular disease. In this report, CBO discusses how it would estimate the budgetary effects of policies that sought to increase the use of gene therapy treatment for sickle cell disease (SCD). CBO focuses on SCD because two new gene therapies were recently approved for its treatment, and the first few patients outside clinical trials have been treated with those therapies.

JEL-codes: H51 I13 I18 I38 (search for similar items in EconPapers)
Date: 2024-12-31
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.cbo.gov/system/files/2024-12/60775-sickle-cell-disease_final.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cbo:report:60775

Access Statistics for this paper

More papers in Reports from Congressional Budget Office Contact information at EDIRC.
Bibliographic data for series maintained by ().